Financial Performance - The company's revenue for Q1 2022 was ¥47,566,231.83, a decrease of 76.92% compared to ¥206,120,330.21 in the same period last year[5] - Net profit attributable to shareholders was ¥832,287.46, down 68.43% from ¥2,636,189.61 year-on-year[5] - The total operating revenue for the first quarter was CNY 47,566,231.83, a significant decrease from CNY 206,120,330.21 in the previous period[29] - The net profit for the first quarter of 2022 was CNY 689,639.58, a decrease of 42.9% compared to CNY 1,207,677.17 in the same period of the previous year[32] - The total profit for the first quarter was CNY 1,391,705.62, up from CNY 462,827.63, indicating a significant increase[32] - The operating profit for the first quarter was CNY 1,395,528.98, compared to CNY 463,595.64 in the previous year, showing a substantial improvement[32] - The company reported a basic and diluted earnings per share of CNY 0.0021, down from CNY 0.0066 in the same period last year[32] - The company experienced a decrease in sales revenue from CNY 139,970,046.70 to CNY 54,659,735.81 in the first quarter[33] - The total comprehensive income for the first quarter was CNY 689,639.58, compared to CNY 1,207,677.17 in the previous year[32] Cash Flow and Liquidity - The net cash flow from operating activities improved by 67.97%, reaching -¥10,187,664.02 compared to -¥31,810,151.06 in the previous year[11] - The cash flow from operating activities was negative at CNY -10,187,664.02, an improvement from CNY -31,810,151.06 in the previous year[34] - Cash and cash equivalents decreased from CNY 102,038,663.73 at the beginning of the year to CNY 87,288,618.35 by March 31, 2022[25] - Cash and cash equivalents at the end of the period were CNY 87,288,618.35, down from CNY 131,569,109.02 at the end of the previous year[35] - The cash inflow from investment activities was CNY 217,193,317.64, while cash outflow was CNY 221,755,699.00, resulting in a net cash flow of CNY -4,562,381.36[34] Assets and Liabilities - The company's total assets decreased by 1.21% to ¥817,236,417.04 from ¥827,279,853.47 at the end of the previous year[5] - The total assets as of March 31, 2022, were CNY 817,236,417.04, down from CNY 827,279,853.47 at the beginning of the year[28] - The total liabilities decreased from CNY 148,985,664.02 at the beginning of the year to CNY 138,252,588.01 by March 31, 2022[27] - The company’s total equity as of March 31, 2022, was CNY 678,983,829.03, slightly up from CNY 678,294,189.45 at the beginning of the year[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 83,678[13] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 40.58% of shares, totaling 162,504,262 shares, with 27,000,000 shares pledged[13] - The second largest shareholder, Lixing Industrial Co., Ltd., holds 19.18% of shares, totaling 76,824,043 shares[13] Research and Development - Research and development expenses decreased by 29.20% to ¥3,865,773.86 from ¥5,459,852.75 year-on-year[10] - Research and development expenses for the first quarter were CNY 3,865,773.86, down from CNY 5,459,852.75 in the previous period[29] - The company did not report any new product launches or technological advancements during this quarter[5] - The company has not disclosed any new product or technology developments in the current report[18] Subsidiary and Equity Transfers - The company has transferred the equity of its subsidiary, Yunnan Longjin Pharmaceutical Sales Co., Ltd., in October 2021, which significantly impacted revenue and cost figures[10] - The company has completed the transfer of 51% equity in its subsidiary, Yunnan Longjin Pharmaceutical Sales Co., Ltd., for a total price of 37,336,000 RMB[20] - The company has provided guarantees for its subsidiary, Yunnan Longjin Pharmaceutical Sales Co., Ltd., with a total guarantee amount of up to 25 million RMB[18] - As of March 31, 2022, the guarantee balance for Yunnan Longjin Pharmaceutical Sales Co., Ltd. is 24,994,000 RMB[21] - The company has not yet signed a profit compensation agreement with the original shareholders of Muya Agriculture regarding the performance shortfall[23] Legal and Procurement Issues - The company is currently involved in a legal dispute regarding the validity of a share transfer contract, which may impact future profits[16] - The company participated in a centralized procurement for traditional Chinese medicine, with a proposed winning price of 75.31 RMB per box, representing a 67% decrease from the current procurement price[15] - The company has not signed any procurement documents related to the centralized procurement, leading to uncertainty in expected procurement volume and actual sales[15] Investment Income - The company recorded a decrease in investment income by 28.04%, amounting to ¥1,522,721.95 compared to ¥2,115,982.24 in the previous year[11] - The company reported a significant increase in investment income from joint ventures, with losses of CNY -159,893.11 compared to CNY -141,687.20 in the previous year[32]
龙津药业(002750) - 2022 Q1 - 季度财报